查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992389

支氣管痙攣治療市場：2026-2032年全球市場預測（按治療方法、藥物類別、給藥途徑、分銷管道和最終用戶分類）

Bronchial Spasms Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，支氣管痙攣治療市場價值將達到 3.2386 億美元，到 2026 年將成長至 3.3725 億美元，到 2032 年將達到 4.4077 億美元，年複合成長率為 4.50%。

主要市場統計數據
基準年 2025 3.2386億美元
預計年份：2026年 3.3725億美元
預測年份 2032 4.4077億美元
複合年成長率 (%) 4.50%

對現代支氣管痙攣治療路徑中的臨床挑戰、治療方法多樣性、患者需求和相關人員決策因素進行了權威概述。

支氣管痙攣是一種陣發性且常反覆發作的疾病，其特徵是下呼吸道收縮，對患者和臨床診療帶來沉重負擔。其病理生理機轉涉及氣道高反應性，伴隨平滑肌收縮、黏膜水腫和多種發炎過程，因此需要採取快速緩解症狀和預防復發的策略。臨床醫師必須平衡急性期治療和長期控制氣道炎症，這種平衡會影響不同醫療機構的治療方法選擇。因此，治療方案包括以器械為基礎的給藥系統、注射生物製劑和全身性用藥，以及針對不同作用機制的口服藥物。

精準醫療、先進的吸入平台和不斷發展的護理模式如何重塑支氣管痙攣治療的臨床選擇和商業性路徑。

近年來，支氣管痙攣的治療發生了變革性變化，這得益於治療方法和醫療服務模式的同步進步。在治療方面，臨床工具箱不斷擴充，包括精準生物製藥和最佳化的吸入技術，從而能夠針對不同表現型的患者群體進行更個人化的干涉。與藥物治療的進步相輔相成的是，粉劑和氣霧劑給藥裝置的創新，這些創新強調給藥的精準性、易用性和對患者用藥依從性的支持，共同改變了臨床醫生選擇和處方治療方法的方式。數位化用藥依從性工具和遠端監測的整合進一步強化了這些變革，使得患者能夠在獨立的臨床環境之外進行長期管理。

評估 2025 年美國關稅變化對支氣管痙攣治療的供應鏈、製造經濟、籌資策略和臨床連續性的實際影響。

美國2025年實施的關稅調整的累積影響正對支氣管痙攣治療生態系統中的所有相關人員產生實際影響。由於關稅上漲，原料藥、計量閥和特殊聚合物等醫療設備組件以及進口生產設備的成本增加，給生產效率帶來了上行壓力。為此，贊助商和契約製造製造商正試圖透過審查與供應商的合約、加快雙重採購策略以及在某些情況下將關鍵組裝流程轉移到更靠近主要市場的地方來降低貿易政策變化帶來的風險。

詳細的細分分析將治療方法、劑型、藥物類別、通路和醫療保健環境與影響臨床引入和商業化的因素聯繫起來。

精細化的細分觀點清楚地展現了治療創新與商業性機會在治療方法類型、藥物類別、給藥途徑、分銷管道和終端用戶等各個層面的交匯點。對治療方法類型的檢驗揭示了一個多面向的格局，其中吸入療法、注射劑和口服藥物各自發揮不同的作用。在吸入療法中，乾粉吸入器、定量吸入器和霧化器各自展現出不同的給藥方案。乾粉吸入器可細分為多劑量型和單劑量型，而霧化器則分為噴射式、網式和超音波技術。注射劑包括氨茶鹼類藥物、生物製劑和全身性糖皮質激素，其中生物製劑可細分為美泊利單抗、Omalizumab和瑞利珠單抗等藥物。口服藥物包括抗膽鹼能藥物、支氣管擴張劑、聯合治療和皮質類固醇。抗膽鹼能藥物分為長效和短效兩種類型，支氣管擴張劑分為長效和短效BETA受體激動劑，皮質類固醇有吸入劑和全身給藥劑兩種劑型。

美洲、歐洲、中東和非洲以及亞太地區在監管、支付方和基礎設施方面的區域差異如何影響採用趨勢和獲取策略？

區域趨勢顯著影響全球支氣管痙攣藥物的採納、報銷和臨床應用。在美洲，與保險公司的密切合作、對降低住院率療效的重視以及先進吸入裝置的廣泛應用，往往是推動臨床應用的主要因素。該地區的市場進入策略通常優先考慮獲取可靠的真實世界數據（REW）以及為呼吸科專家和基層醫療網路開展相關人員教育。在歐洲、中東和非洲，監管的多樣性和報銷系統的差異導致了多種多樣的准入途徑。區域醫療技術評估要求和採購慣例制定個人化的實證文件和彈性價格設定方法。同時，在亞太地區，數位醫療的快速發展、對國內生產能力的日益重視以及支付方成熟度的差異，正在影響著給藥途徑和配銷通路的選擇，其中在線藥房和居家照護服務在某些市場正迅速擴張。

製藥、醫療設備和數位領域新參與企業的競爭行為分析：以合作、證據產生和製造敏捷性為差異化因素

支氣管痙攣治療領域的競爭格局呈現出多元化的態勢，既有成熟的製藥和醫療設備公司，也有新興的專業研發企業，以及數量不斷成長的數位醫療參與企業。擁有廣泛呼吸系統產品系列的成熟企業往往透過整合製劑、醫療設備工程和全球分銷等能力來維持市場地位，而小規模的專業公司則專注於獨特的作用機制和差異化的給藥技術，力求在細分市場中佔據一席之地。醫療設備和生物製藥研發企業之間日益密切的合作，正在催生旨在提高患者用藥依從性和改善臨床療效的綜合解決方案。

針對製造商和醫療保健提供者的具體策略行動，以加強供應韌性、促進用藥依從性、創建引人注目的真實世界數據 (REW) 並加快獲取途徑。

產業領導者應優先考慮一系列兼顧臨床價值和商業性韌性的實質措施。首先，應實現關鍵零件和原料籌資策略的多元化，以降低關稅和地緣政治動盪帶來的風險，並評估近岸外包和雙重採購的機會，以縮短前置作業時間。其次，應投資開發醫療設備的易用性和用藥依從性支持工具，並將客觀的用藥依從性指標和病患教育融入產品中，以改善治療效果並提高支付方的接受度。第三，應制定嚴謹的真實世界證據產生計劃，以收集符合支付方要求的具有臨床意義的終點和衛生經濟學結果，從而促進獲得有利的准入決策。

我們將以透明的方式解釋一種多來源調查方法，該方法結合了臨床醫生的見解、文獻整合和交叉檢驗分析，以得出嚴謹的行業知識。

本分析採用定性和定量相結合的研究途徑，以確保對臨床實踐、醫療設備應用、支付方行為和供應趨勢進行全面、多角度的洞察。主要調查包括對呼吸科醫生、呼吸科護理師、採購經理和報銷專家的結構化訪談，以了解他們對治療方法選擇、醫療設備易用性和獲取障礙的實際觀點。次要證據來自同行評審的臨床文獻、監管指導文件、醫療設備性能規範和已發布的臨床指南，用於闡釋主要研究結果並驗證基於機制的檢驗。

我們簡潔地整合了治療、營運和政策的趨勢，重點強調了將創新轉化為臨床影響和商業性成功的策略重點。

總之，支氣管痙攣的治療正在經歷重大變革，這主要得益於標靶治療、給藥技術和醫療服務模式的進步。這些變革為改善患者預後創造了機遇，具體體現在：更精準的治療方法與疾病表現型匹配、透過先進的吸入和霧化系統實現更可靠的藥物輸送，以及加強對患者用藥依從性的監測。同時，貿易政策的變化和區域監管差異等宏觀經濟因素迫使企業更加謹慎地審視其生產、採購和打入市場策略。成功的企業將是那些能夠將臨床創新與營運韌性相結合，並創造符合支付方期望的實證醫學證據的企業。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按治療類型分類的支氣管痙攣治療市場

  • 吸入療法
    • 乾粉吸入器
      • 多劑量乾粉吸入劑
      • 單劑量乾粉吸入器
    • 定量吸入器
    • 噴霧器
      • 噴射式霧化器
      • 篩孔式噴霧器
      • 超音波霧化器
  • 注射藥物
    • 氨茶鹼
    • 生物製藥
      • 美泊利單抗
      • Omalizumab
      • 雷利茲瑪
    • 全身性類固醇
  • 口服藥物
    • 抗膽鹼能藥物
      • 長效抗膽鹼能藥物
      • 短效抗膽鹼能藥物
    • 支氣管擴張劑
      • 長效BETA-激動劑
      • 短效BETA-激動劑
    • 聯合治療
    • 皮質類固醇
      • 吸入性類固醇
      • 全身性類固醇

第9章 支氣管痙攣治療市場：依藥物類別分類

  • 抗膽鹼能藥物
  • BETA-激動劑
  • 皮質類固醇
    • 吸入性皮質類固醇
    • 全身性皮質類固醇
  • 白三烯調節劑
    • Montelukast
    • 札菲爾·盧卡斯特
    • 吉留頓

第10章 支氣管痙攣治療市場：依給藥途徑分類

  • 吸入
    • 氣霧劑
    • 乾粉
    • 噴霧器
  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服
    • 膠囊
    • 糖漿
    • 藥片
  • 經皮
    • 凝膠
    • 修補

第11章 支氣管痙攣治療市場：依通路分類

  • 線上
  • 離線

第12章 支氣管痙攣治療市場：依最終使用者分類

  • 門診手術中心
  • 診所
  • 居家照護
  • 醫院

第13章 支氣管痙攣治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 支氣管痙攣治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 支氣管痙攣治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國支氣管痙攣治療市場

第17章：中國支氣管痙攣治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amphastar Pharmaceuticals, Inc
  • Bayer AG
  • CH Boehringer Sohn AG & Co. KG
  • CHIESI Farmaceutici SpA
  • Cipla Limited
  • GlaxoSmithKline plc
  • Grifols, SA
  • Lybrate, Inc.
  • Merck KGaA
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc
  • Temple University Health System, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group Ltd by Philip Morris International Inc.
  • Viatris Inc.
Product Code: MRR-3204321AF1B0

The Bronchial Spasms Treatment Market was valued at USD 323.86 million in 2025 and is projected to grow to USD 337.25 million in 2026, with a CAGR of 4.50%, reaching USD 440.77 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 323.86 million
Estimated Year [2026] USD 337.25 million
Forecast Year [2032] USD 440.77 million
CAGR (%) 4.50%

An authoritative overview of bronchial spasm clinical imperatives, therapeutic diversity, patient needs, and stakeholder decision drivers in modern care pathways

Bronchial spasms are episodic but frequently recurrent constrictive events of the lower airways that impose significant clinical burden on patients and clinical pathways. The pathophysiology involves hyperreactive airways with smooth muscle constriction, mucosal edema, and variable inflammatory processes that require rapid symptom relief as well as strategies to prevent recurrence. Clinicians balance acute management with long-term modulation of airway inflammation, and this balance shapes therapeutic choices across numerous care settings. As a result, the treatment landscape includes device-based delivery systems, injectable biologics and systemic agents, and oral therapies that address different mechanistic targets.

Against this clinical backdrop, stakeholders must navigate device usability, adherence dynamics, regulatory expectations, and evolving reimbursement environments that influence product adoption. Patients increasingly demand treatments that minimize exacerbation risk while preserving quality of life, and payers prioritize therapies that reduce hospital encounters and downstream costs. Consequently, industry participants are under pressure to demonstrate real-world effectiveness, patient-centered design, and cost-effectiveness in order to secure favorable uptake across ambulatory clinics, hospital systems, and home-care settings. This introduction frames the subsequent sections by highlighting the intersection of clinical need, therapeutic diversity, and commercial imperatives.

How precision therapeutics, advanced inhalation platforms, and care model evolution are reshaping clinical choices and commercial pathways for bronchial spasm management

Recent years have seen transformative shifts in bronchial spasms treatment driven by simultaneous advances in therapeutic modalities and care delivery models. On the therapeutic front, precise biologic agents and optimized inhalation technologies have broadened the clinical toolkit, allowing more tailored interventions for phenotypically distinct patient cohorts. Complementing pharmacologic progress, device innovation in powder and aerosol delivery has emphasized dosing accuracy, ease of use, and adherence support, which together are shifting how clinicians select and prescribe therapies. These changes are amplified by greater integration of digital adherence tools and remote monitoring, enabling longitudinal patient management beyond episodic clinic encounters.

Regulatory and reimbursement environments have evolved in parallel, with payers increasingly requesting robust real-world evidence and value-based outcomes that demonstrate reductions in acute care utilization. Meanwhile, supply chain resilience and manufacturing agility have gained prominence due to prior disruptions, prompting sponsors to diversify sourcing and localize critical components. In sum, the landscape is moving toward personalized, evidence-driven care pathways that couple targeted therapies with advanced delivery systems and data-rich performance measurement, reshaping clinical practice and commercial strategies alike.

Assessment of the practical effects of 2025 United States tariff changes on supply chains, manufacturing economics, procurement strategies, and clinical continuity for bronchial spasm treatments

The cumulative effects of the United States tariff adjustments implemented in 2025 have introduced practical implications for participants across the bronchial spasms treatment ecosystem. Tariff-driven increases in the cost of active pharmaceutical ingredients, device components such as metering valves and specialized polymers, and imported manufacturing equipment have exerted upward pressure on production economics. Sponsors and contract manufacturers have responded by re-examining supplier contracts, accelerating dual-sourcing strategies, and in some cases relocating critical assembly steps closer to key markets to mitigate exposure to trade policy volatility.

Beyond direct cost impacts, tariffs have influenced strategic prioritization of capital expenditure, with manufacturers weighing the returns of investing in localized production against the benefits of maintaining globalized supply chains. Payers and providers have also felt secondary effects; procurement negotiations now factor in longer lead times and potential price variability, which can affect formulary positioning and purchasing cadence. Looking forward, the industry is adapting through a combination of contractual hedging, increased inventory buffers for critical components, and collaborative engagements with logistics partners to preserve continuity of care without compromising regulatory compliance or clinical quality standards.

In-depth segmentation analysis linking therapeutic modalities, delivery formats, drug classes, channels, and care settings to clinical adoption and commercialization levers

A granular segmentation lens clarifies where therapeutic innovation and commercial opportunity intersect across treatment types, drug classes, administration routes, distribution channels, and end users. Examining treatment type reveals a multi-modal landscape in which inhalation therapy, injectable medications, and oral medications play distinct roles. Within inhalation therapy, dry powder inhalers, metered dose inhalers, and nebulizers represent differentiated delivery profiles; dry powder devices subdivide into multi-dose and single-dose formats, while nebulizers split into jet, mesh, and ultrasonic technologies. Injectable options include aminophylline, biologics, and systemic steroids, with biologics further differentiated by agents such as mepolizumab, omalizumab, and reslizumab. Oral medications encompass anticholinergics, bronchodilators, combination therapies, and corticosteroids, with anticholinergics separating into long-acting and short-acting variants and bronchodilators into long-acting and short-acting beta agonists, while corticosteroids appear as inhaled and systemic formulations.

When viewed by drug class, distinctions among anticholinergics, beta agonists, corticosteroids, and leukotriene modifiers influence prescribing patterns and payer assessments, and subclasses within each category affect clinical positioning. Route of administration further refines opportunity sets: inhalation modalities span aerosol, dry powder, and nebulization approaches; injectables cover intramuscular, intravenous, and subcutaneous routes; oral therapies are delivered in capsule, syrup, or tablet formats; and transdermal options include gels and patches. Distribution channel dynamics shape access and patient experience, with clinics, hospital pharmacies, online pharmacies, and retail pharmacies each subdivided by practice type or retail model. Finally, end-user segmentation highlights distinct care settings-ambulatory surgical centers, clinics, home care, and hospitals-with outpatient and specialist clinics as key subsegments and private and public hospital distinctions that affect procurement and clinical protocols. Together, these segmentation layers inform product design, commercialization tactics, and evidence generation priorities by aligning therapeutic attributes to the operational realities of each channel and user type.

How regional regulatory, payer, and infrastructure differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape adoption dynamics and access strategies

Regional dynamics materially influence how bronchial spasms therapies are adopted, reimbursed, and integrated into clinical practice across the globe. In the Americas, clinical adoption tends to be driven by strong payer engagement, emphasis on outcomes that reduce hospital utilization, and widespread availability of advanced inhalation devices; market access strategies there typically prioritize robust real-world evidence and stakeholder education for pulmonologists and primary care networks. In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement systems create a mosaic of access pathways, where localized health technology assessment requirements and procurement practices necessitate tailored evidence dossiers and flexible pricing approaches. Meanwhile, in the Asia-Pacific region, rapid uptake of digital health, a growing emphasis on domestic manufacturing capability, and varied payer maturity influence both route-of-administration preferences and distribution channel choices, with online pharmacies and home-care services expanding rapidly in certain markets.

Across all regions, differences in clinician training, patient preferences, and healthcare infrastructure shape which delivery systems and therapeutic classes gain traction. These regional contrasts underscore the need for differentiated commercialization plans, adaptive clinical support programs, and supply chain footprints that align with regulatory timelines and local procurement norms. Consequently, strategic planning must incorporate region-specific evidence generation, stakeholder engagement, and logistical arrangements to ensure treatment innovations translate into measurable improvements in patient outcomes and care continuity.

Analysis of competitive behaviors among pharmaceutical, device, and digital entrants emphasizing collaboration, evidence generation, and manufacturing agility as differentiators

Competitive dynamics in the bronchial spasms treatment space reflect a blend of established pharmaceutical and device players, emerging specialty developers, and a growing cohort of digital health entrants. Incumbent firms with broad respiratory portfolios tend to leverage integrated capabilities-spanning formulation, device engineering, and global distribution-to sustain market presence, while smaller specialist companies focus on novel mechanisms or differentiated delivery technologies to carve niche positions. Collaboration between device and biologic developers has become more frequent, producing combination solutions that aim to improve adherence and clinical outcomes.

Strategic priorities among companies include strengthening clinical pipelines with targeted indications, investing in user-centric device design to reduce misuse, and generating robust real-world evidence to satisfy payer demands. Manufacturing agility and regulatory savvy are also competitive differentiators, as firms that can localize production, expedite regulatory submissions, and provide post-market safety data tend to achieve smoother market entry. Mergers, strategic partnerships, and licensing arrangements remain important mechanisms for accelerating access to complementary capabilities, while commercialization success often hinges on the depth of clinical stakeholder relationships and the ability to demonstrate measurable reductions in acute care episodes.

Concrete strategic actions for manufacturers and providers to strengthen supply resilience, drive adherence, generate compelling real-world evidence, and accelerate access

Industry leaders should prioritize a set of pragmatic actions that align clinical value with commercial resilience. First, diversify sourcing strategies for critical components and raw materials to reduce exposure to tariff-related and geostrategic disruptions, while evaluating opportunities for nearshoring or dual-sourcing to shorten lead times. Second, invest in device usability and adherence support tools, integrating objective adherence measures and patient education into product offerings to improve therapeutic outcomes and payer receptivity. Third, develop rigorous real-world evidence generation plans that capture clinically meaningful endpoints and health economic outcomes aligned with payer requirements to facilitate favorable access decisions.

Additionally, forge collaborative partnerships with healthcare systems and specialty clinics to streamline patient pathways and collect longitudinal outcome data that demonstrate value. Enhance regulatory engagement early to align clinical development with regional submission expectations, and consider staged rollouts that prioritize high-value care settings. Finally, adopt flexible pricing and contracting approaches, including outcome-based arrangements where appropriate, to lower payer barriers and accelerate adoption. Implementing these strategies will help organizations translate scientific advances into durable clinical impact and sustainable commercial performance.

Transparent description of multi-source research techniques combining clinician insights, literature synthesis, and cross-validated analysis to produce rigorous industry findings

The research approach underpinning this analysis combined qualitative and quantitative techniques to ensure balanced, multi-source insight into clinical practice, device adoption, payer behavior, and supply dynamics. Primary research included structured interviews with pulmonologists, respiratory nurses, procurement leaders, and reimbursement specialists to capture frontline perspectives on treatment selection, device usability, and access barriers. Secondary evidence was synthesized from peer-reviewed clinical literature, regulatory guidance documents, device performance specifications, and published clinical guidelines to contextualize primary findings and to validate mechanistic rationale.

Analytical rigor was achieved through cross-validation of themes across data sources, targeted case studies of representative product launches, and scenario-based analysis of supply chain and policy shocks. Limitations of the methodology are acknowledged: stakeholder interviews may reflect practice variation, and publicly available literature may lag the most recent commercial developments. To mitigate these constraints, the study applied conservative interpretation of emerging trends and prioritized triangulated findings that appeared consistently across independent sources. Where relevant, the research identifies evidence gaps and recommends follow-up primary studies to address critical uncertainties.

Concise synthesis of therapeutic, operational, and policy dynamics highlighting strategic priorities for converting innovation into clinical impact and commercial success

In summary, bronchial spasms treatment is undergoing a phase of substantive evolution driven by advances in targeted therapeutics, delivery technologies, and care delivery models. These shifts create opportunities to improve patient outcomes through better matching of therapeutic modality to phenotype, more reliable delivery through refined inhalation and nebulization systems, and enhanced adherence monitoring. At the same time, macro forces such as trade policy changes and regional regulatory heterogeneity require companies to be more deliberate in their manufacturing, sourcing, and market-entry strategies. Successful organizations will be those that combine clinical innovation with operational resilience and evidence generation tailored to payer expectations.

Decision-makers should view the current environment as one where coordinated investments across product design, clinical evidence programs, and supply chain architecture can yield competitive advantage. By aligning technical development with stakeholder needs and regional access dynamics, leaders can convert scientific promise into reproducible clinical benefit and sustainable commercial performance. The following call to action outlines options for acquiring the full report and arranging targeted briefings to translate these insights into immediate strategic plans.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchial Spasms Treatment Market, by Treatment Type

  • 8.1. Inhalation Therapy
    • 8.1.1. Dry Powder Inhalers
      • 8.1.1.1. Multi-Dose Dpi
      • 8.1.1.2. Single-Dose Dpi
    • 8.1.2. Metered Dose Inhalers
    • 8.1.3. Nebulizers
      • 8.1.3.1. Jet Nebulizers
      • 8.1.3.2. Mesh Nebulizers
      • 8.1.3.3. Ultrasonic Nebulizers
  • 8.2. Injectable Medications
    • 8.2.1. Aminophylline
    • 8.2.2. Biologics
      • 8.2.2.1. Mepolizumab
      • 8.2.2.2. Omalizumab
      • 8.2.2.3. Reslizumab
    • 8.2.3. Systemic Steroids
  • 8.3. Oral Medications
    • 8.3.1. Anticholinergics
      • 8.3.1.1. Long-Acting Anticholinergics
      • 8.3.1.2. Short-Acting Anticholinergics
    • 8.3.2. Bronchodilators
      • 8.3.2.1. Long-Acting Beta Agonists
      • 8.3.2.2. Short-Acting Beta Agonists
    • 8.3.3. Combination Therapies
    • 8.3.4. Corticosteroids
      • 8.3.4.1. Inhaled Steroids
      • 8.3.4.2. Systemic Steroids

9. Bronchial Spasms Treatment Market, by Drug Class

  • 9.1. Anticholinergics
  • 9.2. Beta Agonists
  • 9.3. Corticosteroids
    • 9.3.1. Inhaled Corticosteroids
    • 9.3.2. Systemic Corticosteroids
  • 9.4. Leukotriene Modifiers
    • 9.4.1. Montelukast
    • 9.4.2. Zafirlukast
    • 9.4.3. Zileuton

10. Bronchial Spasms Treatment Market, by Route Of Administration

  • 10.1. Inhalation
    • 10.1.1. Aerosol
    • 10.1.2. Dry Powder
    • 10.1.3. Nebulization
  • 10.2. Injectable
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Syrup
    • 10.3.3. Tablet
  • 10.4. Transdermal
    • 10.4.1. Gel
    • 10.4.2. Patch

11. Bronchial Spasms Treatment Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Bronchial Spasms Treatment Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals

13. Bronchial Spasms Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchial Spasms Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchial Spasms Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bronchial Spasms Treatment Market

17. China Bronchial Spasms Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amphastar Pharmaceuticals, Inc
  • 18.6. Bayer AG
  • 18.7. C.H. Boehringer Sohn AG & Co. KG
  • 18.8. CHIESI Farmaceutici S.p.A.
  • 18.9. Cipla Limited
  • 18.10. GlaxoSmithKline plc
  • 18.11. Grifols, S.A.
  • 18.12. Lybrate, Inc.
  • 18.13. Merck KGaA
  • 18.14. Novartis AG
  • 18.15. Orion Corporation
  • 18.16. Pfizer Inc
  • 18.17. Temple University Health System, Inc.
  • 18.18. Teva Pharmaceutical Industries Ltd
  • 18.19. Vectura Group Ltd by Philip Morris International Inc.
  • 18.20. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST BR